What is Kailera Therapeutics's D&A?

Kailera Therapeutics (KLRA) reported D&A of $101K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Kailera Therapeutics (KLRA) D&A — Quarterly & Annual

Screener

D&A at other companies

BKBK

$415M-7.0%

GPA

General Purpose Acquisition Corp.GPAC

$992+29.8%

Schering-PloughSGP

$153K+126%

Dycom IndustriesDY

$111.64M+91.2%

Dollar GeneralDG

$270.83M+7.1%

TargetTGT

$685M+4.6%

Other financials

Income statement

See full

Operating income-$84.7M-314%

Net income-$78.9M-339%

EPS (diluted)-$3,650.00+79.7%

Balance sheet

See full

Cash & equivalents$111.8M+9.9%

Total debt$10.5M—

Total equity-$432.1M-83.7%

Total assets$624.8M—

Cash flow

See full

Operating cash flow-$68.3M-275%

Valuation

See full

Market cap$2.44B-15.8%

Enterprise value$2.34B—

Returns & leverage

See full

Debt / equity-0×—

Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →

Filed: May 26, 2026, 4:29 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-239417

FAQ

What is Kailera Therapeutics's D&A?: Kailera Therapeutics (KLRA) reported D&A of $101K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Kailera Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Kailera Therapeutics KLRA D&A

D&A at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Returns & leverage

Where this comes from

FAQ

Ask your AI about Kailera Therapeutics's d&a.